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SCIENTIFIC OPINION
Scientific Opinion on Flavouring Group Evaluation 212 Revision 3
(FGE.212Rev3): α,β-unsaturated alicyclic ketones and precursors from 
chemical subgroup 2.6 of FGE.191
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
(CEF)2,3
European Food Safety Authority (EFSA), Parma, Italy
The scientific opinion FGE.212 Revision 3 published on 28 May 2015, replaces FGE.212 Revision 2 published
on 19 February 20144
ABSTRACT
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety
Authority was requested to evaluate the genotoxic potential of 22 flavouring substances from subgroup 2.6 of
FGE.19 in the Flavouring Group Evaluation 212. Based on available genotoxicity data and new genotoxicity
data submitted by the Industry, the Panel concluded that genotoxic potential could be ruled out for the six
carvone derivatives [FL-no: 02.062, 07.146, 07.147, 09.143, 09.215 and 09.870], the 11 isophorone derivatives
[FL-no: 02.083, 02.101, 07.035, 07.098, 07.126, 07.129, 07.172, 07.175, 07.196, 07.202 and 07.255] and the
five substances [FL-no: 07.033, 07.094, 07.112, 07.140 and 07.219] from subgroup 2.6 in FGE.212,
FGE.212Rev1 and FGE.212Rev3, respectively. Two substances previously included in FGE.212Rev2, vetiverol
and vetiveryl acetate [FL-no: 02.214 and 09.821], are no longer supported by Industry. Based on the available
data, all 22 substances of this FGE are no longer of concern with respect to genotoxicity and can be evaluated
through the Procedure.
© European Food Safety Authority, 2015
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4 The present scientific opinion, FGE.212 Revision 3, includes the additional information on vetiverol [FL-no: 02.214] and
vetiveryl acetate [FL-no: 09.821] received after the publication of FGE.212 Revision 2.
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SUMMARY
Following a request from the European Commission, the (EFSA) Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on
the implications for human health of chemically defined flavouring substances used in or on foodstuffs
in the Member States. In particular, the Panel was asked to evaluate flavouring substances using the
Procedure referred to in Commission Regulation (EC) No 1565/2000 (hereafter ‘the Procedure’).
The present revision of FGE.212, FGE.212 Rev3, deals with the evaluation of additional genotoxicity
data submitted by the Flavour Industry on the representative substance 3-methyl-2-cyclopenten-1-one
[FL-no: 07.112]. Furthermore, since the last revision of FGE.212 (revision 2), the Flavour Industry has
informed EFSA that in the case of two flavouring substances, vetiverol [FL-no: 02.214] and vetiveryl
acetate [FL-no: 09.821], information previously submitted to the European Commission, and on which
EFSA’s evaluation was based, was incorrect regarding the name, structure and composition of these
substances. The use of these two substances as chemically defined flavouring substances is no longer
supported by the Industry.
Flavouring Group Evaluation 212 (FGE.212) concerns 22 substances. The 22 substances correspond to
subgroup 2.6 of FGE.19. Sixteen of these substances are α,β-unsaturated alicyclic ketones [FL-no: 
07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 07.146, 07.147, 07.172, 07.175,
07.196, 07.202, 07.219 and 07.255] and six are precursors for such ketones [FL-no: 02.062, 02.083,
02.101, 09.143, 09.215 and 09.870].
In the first version of this Opinion, FGE.212, the Panel expressed the following view:
“d-Carvone [FL-no: 07.146] was found to be genotoxic in vitro. However, d-carvone was not
carcinogenic in mice. Therefore, the Panel concluded that this substance together with the
structurally related l-carvone as well as carveol and the carvyl derivatives [FL-no: 02.062,
07.147, 09.143, 09.215 and 09.870] could be evaluated through the Procedure.
Isophorone [FL-no: 07.126 (3,5,5-trimethylcyclohex-2-en-1-one)] is genotoxic in vitro and
since there is some evidence of carcinogenicity in male rats and equivocal evidence of
carcinogenicity in male mice and since a non-threshold mechanism could not be excluded based
on the data currently available, the Panel concluded that additional data are required for
isophorone in order to clarify whether genotoxicity occurs in vivo and whether there is a
threshold for the effects observed in the target organs in the long-term bioassays. Therefore, an
in vivo Comet assay in F344/N rats covering these target organs was required in addition to an
in vivo bone marrow assay with oral application.
Due to structural similarities and lack of data, the remaining substances could not be evaluated
through the Procedure [FL-no: 02.083, 02.101, 02.214, 07.033, 07.035, 07.094, 07.098, 07.112,
07.129, 07.140, 07.172, 07.175, 07.196, 07.202, 07.255 and 09.821]. Additional data on
genotoxicity were requested for representative substances of this subgroup according to the
opinion of the Panel on Genotoxicity Test Strategy for Substances Belonging to Subgroups of
FGE.19.”
Based on three sets of additional data submitted by the Industry in response to requested data in
FGE.212, the Panel concluded that:
• the genotoxicity concern for isophorone [FL-no: 07.126] and the substances structurally
related to isophorone [FL-no: 02.083, 02.101, 07.035, 07.098, 07.129, 07.172, 07.175, 07.196,
07.202 and 07.255] could be ruled out.
• New data for 3-methyl-2-cyclopenten-1-one [FL-no: 07.112] can rule out genotoxicity of this
substance and four other substances [FL-no: 07.033, 07.094, 07.140 and 07.219].
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• In the case of the two substances for which new genotoxicity information was submitted and
evaluated in FGE.212Rev2, vetiverol and vetiveryl acetate [FL-no: 02.214 and 09.821], the
Flavour Industry has subsequently informed EFSA that information previously submitted to
European Commission, and on which the EFSA’s previous evaluation was based, was
incorrect regarding the name, structure and composition of these substances. The use of these
two flavouring substances is no longer supported by the Industry. Accordingly, these two
substances will not be considered further in this FGE.
• Based on the available data, the substances considered in this FGE are no longer of concern
with respect to genotoxicity and can be evaluated through the Procedure.
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION
The use of flavouring is regulated under Regulation (EC) No 1334/20085 of the European Parliament
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring
properties for use in and on foods. On the basis of Article 9(a) of this Regulation an evaluation and
approval are required for flavouring substances.
The Union List of flavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20126. The list contains flavouring substances for which the scientific
evaluation should be completed in accordance with Commission Regulation (EC) N° 1565/20007.
On 25 November 2010, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids adopted an opinion on Flavouring Group Evaluation 212, Revision 1 (FGE.212Rev1):
α,β-unsaturated alicyclic ketones and precursors from chemical subgroup 2.6 of FGE.198.
The Panel concluded that the argumentation of Industry to expand its conclusion for the six-carbon
ring members of subgroup 2.6 also to the cyclopentenyl derivatives in this subgroup [FL-no: 07.033,
07.094, 07.112 and 07.140] was considered too limited, given the lack of support from experimental
data. Therefore, additional genotoxicity tests are still required for the representative substance [FL-no:
07.112] already chosen by the Panel. Alternatively, a more thorough explanation (physico-chemical
parameters; experimental underpinning) of the proposed similar reactivity of six- and five-membered
ring substances should be provided by Industry.
The requested data have been submitted by the applicant.
In addition, the flavouring substance [FL-no: 07.219], trans-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-
one, was put in FGE.212 (former FGE.19, subgroup 2.6b: α,β-unsaturated aldehydes and ketones and 
precursors) because of its structure relationship with this group. Although the substance as such is not
mentioned in the data submitted by the applicant, the submitted data are likely to be relevant for [FL-
no: 07.219] as well.
Therefore, this request covers as well the re-evaluation of trans-3-methyl-2-(2-pentenyl)-2-
cyclopenten-1-one [FL-no: 07.219].
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION
The European Commission requests the European Food Safety Authority (EFSA) to finalise its
safety assessment of these flavouring substances in accordance with Commission Regulation (EC)
No 1565/20006.
5 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC)
No 1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008,
p. 34–50.
6 EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012,
p. 1–161.
7 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
8 EFSA Journal 2011;9(3):1923.
Flavouring Group Evaluation 212 Revision 3
EFSA Journal 2015;13(5):4116 6
HISTORY OF THE EVALUATION OF FGE.19 SUBSTANCES
Flavouring Group Evaluation 19 (FGE.19) covers 360 flavouring substances from the European Union
(EU) Register that are α,β-unsaturated aldehydes or ketones, or precursors which could give rise to 
such carbonyl substances via hydrolysis and/or oxidation (EFSA, 2008a).
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity (EFSA, 
2008a). The Panel noted that there were limited genotoxicity data on these flavouring substances but
that positive genotoxicity studies were identified for some substances in the group.
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a
(quantitative) structure–activity relationship (Q)SAR prediction of the genotoxicity of these substances
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE
Models and ISS-Local Models (Gry et al., 2007)).
The Panel noted that for most of these models internal and external validation has been performed, but
considered that the outcome of these validations was not always extensive enough to appreciate the
validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the Panel
considered it inappropriate to totally rely on (Q)SAR predictions at that time and decided not to take
substances through the procedure based on negative (Q)SAR predictions only.
The Panel took note of the (Q)SAR predictions obtained using two ISS Local Models (Benigni and
Netzeva, 2007a, b) and four DTU–NFI MultiCASE Models (Gry et al., 2007; Nikolov et al., 2007) and
the fact that data on in vitro and in vivo genotoxicity, as well as on carcinogenicity, were available for
several substances. Based on these data, the Panel decided that 15 subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3,
2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 2008a) could not be evaluated through the
Procedure due to concern with respect to genotoxicity. Corresponding to these subgroups, 15
Flavouring Group Evaluations (FGEs) were established: FGE.200, 204, 205, 206, 207, 208, 209, 211,
215, 219, 221, 222, 223, 224 and 225.
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions,
that a further scrutiny of the data should take place before requesting additional data from the Flavour
Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 213, 214,
216, 217, 218 and 220. In the case of the substances in FGE.202, 214 and 218, it was concluded that a
genotoxic potential could be ruled out and, accordingly, these substances would be evaluated using the
Procedure. For all or some of the substances in the remaining FGEs, FGE.201, 203, 210, 212, 213,
216, 217 and 220 the genotoxic potential could not be ruled out.
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, the European Food Safety Authority
(EFSA) worked out a list of representative substances for each subgroup (EFSA, 2008c). Likewise an
EFSA genotoxicity expert group worked out a test strategy to be followed in the data retrieval for
these substances (EFSA, 2008b).
The Flavour Industry was requested to submit additional genotoxicity data according to the list of
representative substances and test strategy for each subgroup.
The Flavour Industry has now submitted additional data and the present FGE concerns the evaluation
of these data requested on genotoxicity.
Flavouring Group Evaluation 212 Revision 3
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ASSESSMENT
1. History of the evaluation of the substances in the present Flavouring Group Evaluation
In FGE.212, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
(CEF Panel) concluded that, based on available data, the concern for genotoxicity could be ruled out
for d-carvone and five carvone derivatives in subgroup 2.6 [FL-no: 02.062, 07.147, 09.143, 09.215
and 09.870]. Therefore, these substances could be evaluated through the procedure. In the case of
isophorone [FL-no: 07.126] and the structurally related substances [FL-no: 02.083, 02.101, 02.214,
07.033, 07.035, 07.094, 07.098, 07.112, 07.129, 07.140, 07.172, 07.175, 07.196, 07.202, 07.255 and
09.821] additional genotoxicity data were required according to the Test Strategy (EFSA, 2008b). In
the EFSA Opinion “List of α,β-unsaturated aldehydes and ketones representative of FGE.19 
substances for genotoxicity testing” (EFSA, 2008c), representative flavouring substances were
selected for subgroup 2.6 (Table 1), corresponding to FGE.212, for which additional data on the
genotoxicity were requested.
In FGE.212Rev1, new data on genotoxicity were submitted by Industry on the representative
substance, 3,5,5-trimethylcyclohex-2-en-1-one [FL-no: 07.126]. Based on these data, the Panel
concluded that the concern for genotoxicity could be ruled out for 3,5,5-trimethylcyclohex-2-en-1-one
[FL-no: 07.126] and for the 10 six-carbon-ring members of subgroup 2.6 [FL-no: 02.083, 02.101,
07.035, 07.098, 07.129, 07.172, 07.175, 07.196, 07.202 and 07.255].
After revision 1 of FGE.212, one additional five-carbon ring substance, trans-3-methyl-2-(2-pentenyl)-
2-cyclopenten-1-one [FL-no: 07.219], was included in the FGE.
For the two seven-carbon-ring substances, vetiverol and vetiveryl acetate [FL-no: 02.214 and 09.821]
for which new genotoxicity information was submitted (IOFI, 2012) and evaluated in FGE.212Rev2,
the Flavour Industry has subsequently informed EFSA that information previously submitted to the
European Commission, and on which EFSA’s evaluation was based, was incorrect regarding the
name, structure and composition of these substances. The use of these two substances as chemically
defined flavouring substances is no longer supported by the Industry (EFFA, 2014). Accordingly,
these two substances will not be considered further in this FGE.
The Panel noted that the EFSA Scientific Committee adopted an opinion on carvone (EFSA Scientific
Committee, 2014) and confirmed that there is no concern with respect to genotoxicity.
Revision 3 of FGE.212 (FGE.212Rev3) is due to submission of in vitro genotoxicity data on the five-
carbon-ring members of FGE.212. For the representative substance 3-methyl-2-cyclopenten-1-one
[FL-no: 07.112] an Ames test (Bowen, 2014) and a micronucleus assay in human peripheral blood
lymphocytes (Watters, 2014) have been provided.
The new data provided for [FL-no: 07.112] are also considered to cover the evaluation of a possible
genotoxicity potential of the other four five-carbon-ring members of this FGE [FL-no: 07.033, 07.094,
07.140 and 07.219].
FGE Adopted by EFSA Link No of
substances
FGE.212 27 November 2008 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902780085.htm
23
FGE.212Rev1 25 November 2010 http://www.efsa.europa.eu/en/efsajournal/pub/1923.htm 23
FGE.212Rev2 29 January 2014 http://www.efsa.europa.eu/it/efsajournal/pub/3584.htm 24
FGE.212Rev3 5 May 2015 http://www.efsa.europa.eu/it/efsajournal/pub/4116.htm 22
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Table 1: Representative substances for subgroup 2.6 of FGE.19 (EFSA, 2008c)
FL-no
JECFA-no
Subgroup EU Register name Structural formula
07.112
1105
2.6 3-Methyl-2-cyclopenten-1-
one
07.126
1112
2.6 3,5,5-Trimethylcyclohex-2-
en-1-one (isophorone)
Sections 2, 3 and 4 of this opinion report the same information that was presented in FGE.212 and
FGE.212Rev1. As vetiverol [FL-no: 02.214] and vetiveryl acetate [FL-no: 09.821] are no longer
supported by the Industry, the text in Section 5 has been modified accordingly.
Section 6 describes the new data evaluated in FGE.212Rev3.
2. Presentation of the substances in Flavouring Group Evaluation 212Rev3
2.1. Description
The present Flavouring Group Evaluation 212 Revision 3 (FGE.212Rev3), concerns 22 substances,
which are presented in Table 2. The 22 substances correspond to subgroup 2.6 of FGE.19 (EFSA,
2008a). Sixteen of these substances are α,β-unsaturated alicyclic ketones (α,β-unsaturation in the side 
chain) [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 07.146, 07.147,
07.172, 07.175, 07.196, 07.202, 07.219 and 07.255] and six are precursors of such ketones [FL-no:
02.062, 02.083, 02.101, 09.143, 09.215 and 09.870].
Twenty-one of the substances have previously been evaluated by the Joint Food and Agriculture
Organization of the United Nations (FAO)/World Health Organization (WHO) Expert Committee on
Food Additives (JECFA) at their 51st, 59th and 69th meetings (JECFA, 1999, 2003, 2009). A summary
of their evaluation status by the JECFA is given in Table 3.
As the α,β-unsaturated ketone structure is considered to be structural alerts for genotoxicity (EFSA, 
2008a), the available data on genotoxic or carcinogenic activity of the 16 ketones in FGE.212 [FL-no:
07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 07.146, 07.147, 07.172, 07.175,
07.196, 07.202, 07.219 and 07.255] and one non-Register ketone (2,6-dimethyl-9-(1-
methylethylidene)-bicyclo[5.3.0]dec-2-en-4-one), corresponding to the 22 substances in FGE.212, will
be considered in this FGE.
The Panel also noted that, for one substance [FL-no: 07.033], the Chemical Abstracts Service (CAS)
No, name and chemical structure were not consistent (Table 2). Therefore, clarification is still needed.
The Panel has also taken into consideration the outcome of the predictions from five selected (Q)SAR
models (Benigni and Netzeva, 2007a; Gry et al., 2007; Nikolov et al., 2007) on the 15 ketones FL-no:
07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 07.146, 07.147, 07.172, 07.175,
07.196, 07.202 and 07.255] and one non-Register ketone (2,6-dimethyl-9-(1-methylethylidene)-
bicyclo[5.3.0]dec-2-en-4-one) in this FGE. The (Q)SAR predictions for the 15 ketones and the one
non-Register ketone are shown in Table 4.
O
O
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Table 2: Specification summary of the substances in the Flavouring Group Evaluation 212 Revision 3
FL-no
JECFA-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys. form
Mol. formula
Mol. weight
Solubility (a)
Solubility in ethanol
(b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity (e)
02.062
381
Carveol 2247
2027
99-48-9
Liquid
C10H16O
152.24
Freely soluble
226–227
IR
96%
1.493–1.497
0.947–0.953
02.083
434
p-Menth-1-en-3-ol 3179
10248
491-04-3
Liquid
C10H18O
154.25
232
NMR
97 %
1.4762 (25C),
0.930–0.936
02.101
1404
Pin-2-en-4-ol 3594
10304
473-67-6
Solid
C10H16O
152.24
Very slightly soluble
Soluble
n.a.
63–67
NMR
95 %
n.a.
n.a.
07.033
1115
Isojasmone (f) 3552
167
11050-62-7
Liquid
C11H18O
166.26
144 (13 hPa)
NMR
95 %
1.472–1.477
0.917–0.924
07.035
1111
Tetramethyl
ethylcyclohexenone
(mixture of isomers)
3061
168
17369-60-7
Liquid
C12H20O
180.29
Slightly soluble
Miscible
113–115
NMR
97 %
1.485–1.490
0.927–0.934
OH
OH
HO
O
+
O
OO
29 % 68 %
+
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FL-no
JECFA-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys. form
Mol. formula
Mol. weight
Solubility (a)
Solubility in ethanol
(b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity (e)
07.094
1114
3-Methyl-2-(pent-
2(cis)-enyl)cyclopent-
2-en-1-one
3196
11786
488-10-8
Liquid
C11H16O
164.25
248
NMR
98 %
1.495–1.501
0.942–0.948
07.098
1107
3-Methylcyclohex-2-
en-1-one
3360
11134
1193-18-6
Liquid
C7H10O
110.16
Miscible
Miscible
199–200
NMR
98 %
1.490–1.498
0.967–0.972
07.112
1105
3-Methyl-2-
cyclopenten-1-one
3435
11137
2758-18-1
Liquid
C6H8O
96.12
74 (20 hPa)
NMR
98 %
1.485–1.491
0.968–0.975
07.126
1112
3,5,5-
Trimethylcyclohex-2-
en-1-one
3553
11918,
78-59-1
Liquid
C9H14O
138.21
Slightly soluble
Miscible
213–215
NMR
97 %
1.474–1.481
0.919–0.927
07.129
1113
3-Methyl-5-
propylcyclohex-2-en-1-
one
3577
3720-16-9
Liquid
C10H16O
152.23
Insoluble
Miscible
242–244
NMR
95 %
1.481–1.486
0.924–0.928
07.140
1406
3-Methyl-2-
pentylcyclopent-2-en-
1-one
3763
1128-08-1
Liquid
C11H18O
166.26
Very slightly soluble
Soluble
79 (0.2 hPa)
NMR
99 %
1.676–1.682
0.911–0.917
07.146
380.1
d-Carvone
2244-16-8
C10H14O
150.22
O
O
O
O
O
O
O
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FL-no
JECFA-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys. form
Mol. formula
Mol. weight
Solubility (a)
Solubility in ethanol
(b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity (e)
07.147
380.2
l-Carvone
6485-40-1
C10H14O
150.22
07.172
1110
4-Isopropylcyclohex-2-
en-1-one
3939
11127
500-02-7
Liquid
C9H14O
138.21
Insoluble
Miscible
198
NMR
97 %
1.481–1.490
0.930–0.950
07.175
435
p-Menth-1-en-3-one 2910
2052
89-81-6
Liquid
C10H16O
152.24
Insoluble 233–235
IR
94 %
1.483–1.487
0.929–0.934
07.196
1870
Pin-2-en-4-one 4216
11186
80-57-9
Liquid
C10H14O
150.22
Insoluble
Freely soluble
90 (16 hPa)
NMR MS
95%
1.492–1.498
0.975–0.981
07.202 2,6,6-
Trimethylcyclohex-2-
en-1-one 20013-73-4
Liquid
C9H14O
138.21
Slightly soluble
Freely soluble
63 (16 hPa)
MS
95 %
1.470–1.476
0.924–0.930
07.219 trans-3-Methyl-2-(2-
pentenyl)-2-
cyclopenten-1-one
3196
11786
6261-18-3
Liquid
C11H16O
164.25
Soluble
Soluble
248
MS
98 %
1.495–1.501
0.942–0.948
07.255
1856
l-Piperitone 4200
4573-50-6
Liquid
C10H16O
152.24
Slightly soluble
Freely soluble
246
MS
99 %
1.482–1.488
0.929–0.935
O
O
O
O
O
O
O
R
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FL-no
JECFA-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys. form
Mol. formula
Mol. weight
Solubility (a)
Solubility in ethanol
(b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity (e)
09.143
383
Carvyl propionate 2251
424
97-45-0
Liquid
C13H20O2
208.30
Insoluble 239
IR, 98 %
1.469–1.479
0.942–0.962
09.215
382
Carvyl acetate 2250
2063
97-42-7
Liquid
C12H18O2
194.27
Slightly soluble 229
IR
98 %
1.473–1.479
0.964–0.970
09.870 Carvyl-3-
methylbutyrate
94386-39-7
Liquid
C15H24O2
236.37
Practically insoluble
or insoluble
Freely soluble
343
MS
95 %
1.462–1.468
0.932–0.938
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95 % ethanol, if not otherwise stated.
(c): At 1 013.25 hPa, if not otherwise stated.
(d): At 20 °C, if not otherwise stated.
(e): At 25 °C, if not otherwise stated.
(f): Stereoisomeric composition not specified.
n.a.: not applicable
O
O
OO
O
O
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3. Data available to the Panel in FGE.2129
3.1. (Quantitative) structure–activity relationship predictions
The outcomes of the (Q)SAR predictions for possible genotoxic activity in five in vitro (Q)SAR
models (ISS Local Model-Ames test; and DTU-NFI MultiCASE-Ames test, -Chromosomal aberration
test in Chinese hamster ovary cells (CHO), -Chromosomal aberration test in Chinese hamster lung
cells (CHL) and -Mouse lymphoma test) are presented in Table 4.
Positive predictions have been obtained for six substances with the MultiCASE mouse lymphoma
model and for one of these substances also with the MultiCASE model on chromosomal aberrations.
For the other substances, the predictions of the MultiCASE models were negative or equivocal, or the
substances were out of domain. All substances were out of domain in the ISS model.
3.2. Carcinogenicity studies
Groups of 50 male and 50 female F344/N rats were administered isophorone (3,5,5-trimethylcyclohex-
2-en-1-one [FL-no: 07.126]) in maize oil by gavage at dose levels of 0 (controls), 250 or 500 mg/kg
body weight (bw)/day, five times per week for 103 weeks. During the study, the body weights of the
male and female rats in the high-dose group were slightly lower than those of the vehicle controls. The
survival of male rats in the high-dose group was significantly lower than that of the vehicle-treated
controls after week 96. Dosed male rats showed a variety of proliferative lesions of the kidney (tubular
cell hyperplasia, 0/50, 1/50, 4/50 in the control, 250 mg/kg and 500 mg/kg groups, respectively;
tubular cell adenoma, 0/50, 0/50, 2/50; tubular cell adenocarcinoma, 0/50, 3/50, 0/50; epithelial
hyperplasia of the renal pelvis, 0/50, 5/50, 5/50). Dosed male rats also exhibited increased
mineralisation of the medullary collecting ducts (1/50, 31/50, 20/50) and male rats in the low-dose
group showed a more severe nephropathy than is commonly seen in ageing F344/N rats. The incidence
of carcinomas of the preputial gland was significantly increased (P < 0.03) in male rats in the high-
dose group (0/50, 0/50, 5/50 in the control, 250 mg/kg and 500 mg/kg groups, respectively). With the
exception of a moderate increase in nephropathy (21/50, 39/50, 32/50 in the control, 250 mg/kg and
500 mg/kg groups, respectively), female rats did not show chemically related increased incidences of
neoplastic or non-neoplastic lesions (NTP, 1986).
Groups of 50 male and 50 female B6C3F1 mice were administered isophorone (3,5,5-
trimethylcyclohex-2-en-1-one [FL-no: 07.126]) in maize oil by gavage at dose levels of 0 (controls),
250 or 500 mg/kg bw/day, five times per week for 103 weeks. During the study, the body weights of
female mice in the high-dose group were slightly lower than those of the vehicle controls. The survival
of male mice was low, whereas there was a significant trend towards increased survival of dosed
female mice relative to that of the vehicle controls. In male mice of the high-dose group, isophorone
exposure was associated with an increased incidence of hepatocellular adenomas and carcinomas
(18/48, 18/50, 29/50 in the control, 250 mg/kg and 500 mg/kg groups, respectively) and of
mesenchymal tumours of the integumentary system (fibroma, fibrosarcoma, neurofibrosarcoma or
sarcoma: 6/48, 7/50, 14/50). An increased incidence of lymphomas or leukaemias was noted in male
mice in the low-dose group (8/48, 18/50, 5/50 in the control, 250 mg/kg and 500 mg/kg groups,
respectively). Coagulative necrosis (3/48, 10/50, 11/50) and hepatocytomegaly (23/48, 39/50, 37/50)
were observed more frequently in the livers of dosed male mice than in vehicle controls. No
compound-related neoplastic or non-neoplastic lesions associated with isophorone exposure were seen
in female mice (NTP, 1986).
The Panel concluded that isophorone increased the incidences of renal tubular cell adenomas and
adenocarcinomas and of carcinomas of the preputial gland in male rats but not in female rats. In male
9 The data presented in Section 3 are cited from the first version of the present FGE.212. These data are the basis of the
conclusions in FGE.212 requesting additional genotoxicity data.
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mice, but not in females, it produced increased incidences of hepatocellular adenomas and carcinomas,
mesenchymal tumours in the integumentary system and malignant lymphomas.
The Panel agrees with the authors of the National Toxicology Program (NTP) report, who concluded
that “under the conditions of these 2-year gavage studies, there was some evidence of carcinogenicity
of isophorone in male F344/N rats as shown by the occurrence of renal tubular cell adenomas and
adenocarcinomas in animals given 250 or 500 mg/kg bw per day; carcinomas of the preputial gland
were also observed at increased incidence in male rats given 500 mg/kg bw. There was no evidence of
carcinogenicity in female F344/N rats given 250 or 500 mg/kg bw per day. For male B6C3F1 mice,
there was equivocal evidence of carcinogenicity of isophorone as shown by an increased incidence of
hepatocellular adenomas or carcinomas (combined) and of mesenchymal tumours in the
integumentary system in animals given 500 mg/kg bw per day and by an increase in malignant
lymphomas in animals given 250 mg/kg bw per day. There was no evidence of carcinogenicity of
isophorone in female B6C3F1 mice given 250 or 500 mg/kg bw per day.”
Groups of 50 male and 50 female B6C3F1 mice (7 weeks old) were administered 0, 375 or
750 mg/kg bw d-carvone [FL-no: 07.146] in maize oil by gavage, five days per week for 103 weeks.
The mean body weights of dosed and control male and female mice were similar throughout most of
the study. The survival of females in both the low-dose and the high-dose groups was significantly
greater than that of the controls. No differences in survival were observed between any groups of male
mice. Atrophy of the olfactory epithelium and hyperplasia of the underlying Bowman’s glands
occurred together, with high incidence, in both sexes and in both dosed groups. This effect was found
because of a local effect of d-carvone caused by reflux of the gavage material when the gavage needle
was withdrawn. No increases in tumour incidences were seen in mice administered d-carvone. The
incidences of primary neoplasms in male mice and the total numbers of primary neoplasms were
significantly lower in the dosed groups than in the vehicle controls (NTP, 1990).
The Panel concluded that d-carvone was not carcinogenic in mice under the study conditions. It agrees
with the authors of the NTP report, who concluded that “under the conditions of these 2-year gavage
studies, there was no evidence of carcinogenic activity of d-carvone for male or female B6C3F1 mice
administered 375 or 750 mg/kg, 5 days per week for 2 years.”
Study validation and results are presented in Table 5.
3.3. Genotoxicity studies
Studies are available for four substances in subgroup 2.6. For tetramethyl ethylcyclohexenone
(mixture of isomers) [FL-no: 07.035], one in vitro and one in vivo study have been evaluated.
Seven in vitro and three in vivo studies are available for 3,5,5-trimethylcyclohex-2-en-1-one [FL-no:
07.126] (isophorone).
Three in vitro studies are available concerning d-carvone [FL-no: 07.146] and two in vitro studies
concerning l-carvone [FL-no: 07.147].
Study validation and results are presented in Tables 6 and 7.
3,5,5-Trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) did not induce gene mutations in
bacteria, but it did induce mutations in mammalian cells in a mouse lymphoma thymidine kinase
(MLTK) assay in the absence of metabolic activation (it was not tested in the presence of metabolic
activation) (NTP, 1986). No mutations in the MLTK assay were observed in a study carried out by
O’Donoghue et al. (1988) at comparable concentrations. Isophorone induced chromosomal aberrations
(CA) in CHL fibroblasts with and without metabolic activation (Matsuoka et al., 1996) and sister
chromatid exchanges (SCE) in CHO cells without metabolic activation (Gulati et al., 1989). CA were
not observed in two other studies (NTP, 1986; Gulati et al., 1989); however, the validity of the results
was limited because the types of aberrations were not reported. Isophorone did not induce unscheduled
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DNA synthesis (UDS) in rat hepatocytes in vitro. In vivo, isophorone was tested negative in a sex-
linked recessive lethal mutation assay in Drosophila (Foureman et al., 1994) and in two micronucleus
assays in mice (McKee et al., 1987; O’Donoghue et al., 1988). However, the Drosophila assay has
only limited relevance and the micronucleus assays were of limited validity.
Negative results were also observed with tetramethyl ethylcyclohexenone [FL-no: 07.035] in bacteria,
in a sex-linked recessive lethal mutation assay in Drosophila (Wild et al., 1983) and in a mouse
micronucleus assay (Wild et al., 1983); however, a mixture of isomers was tested and the studies were
of only limited validity.
d-Carvone [FL-no: 07.146] was not mutagenic in bacteria but induced SCE and CA in CHO cells in
the presence and absence of metabolic activation, respectively (NTP, 1990).
3.4. Conclusion on genotoxicity and carcinogenicity
The Panel concluded that 3,5,5-trimethylcyclohex-2-en-1-one [FL-no: 07.126] (isophorone) is
genotoxic in vitro, but a final conclusion on its genotoxicity in vivo could not be drawn based on the
data available. It is carcinogenic in male rats and male mice. It was also predicted to be genotoxic in
one of the four MultiCASE models (whereas it was out of domain in the ISS model).
d-Carvone [FL-no: 07.146] is genotoxic in vitro but no in vivo data were available. d-Carvone is not
carcinogenic in mice and was predicted to be non-genotoxic in the four MultiCASE models (whereas
it was out of domain in the ISS model). No data are available on l-carvone. However, in vivo studies in
humans show that the metabolism of ingestion-correlated amounts of d- or l-carvone occurs via a
major oxidative pathway of the isopropylene side chain, yielding diol and two carboxylic acids,
irrespective of the stereochemical difference between the two parent isomers of carvone (Engel, 2001).
Accordingly, the results for d-carvone can be used for l-carvone as well.
The negative results reported from in vivo studies on the genotoxicity of tetramethyl
ethylcyclohexenone [FL-no: 07.035] are of only limited validity.
3.5. Conclusion
The present Flavouring Group Evaluation 212 (FGE.212) concerns 23 substances. The 23 substances
correspond to subgroup 2.6 of FGE.19. Fifteen of these substances are α,β-unsaturated alicyclic
ketones [FL-no: 07.033, 07.035, 07.094, 07.098, 07.112, 07.126, 07.129, 07.140, 07.146, 07.147,
07.172, 07.175, 07.196, 07.202 and 07.255] and eight are precursors for such ketones [FL-no: 02.062,
02.083, 02.101, 02.214, 09.143, 09.215, 09.821 and 09.870].
d-Carvone [FL-no: 07.146] was found to be genotoxic in vitro. However, d-carvone is not
carcinogenic in mice. Therefore, the Panel concluded that this substance, together with the structurally
related l-carvone, as well as carveol and the carvyl derivatives [FL-no: 02.062, 07.147, 09.143, 09.215
and 09.870], could be evaluated through the Procedure.
Isophorone [FL-no: 07.126] (3,5,5-trimethylcyclohex-2-en-1-one) is genotoxic in vitro and, since there
is some evidence of carcinogenicity in male rats and equivocal evidence of carcinogenicity in male
mice, and since a non-threshold mechanism could not be excluded based on the data currently
available, the Panel concluded that additional data are required for isophorone in order to clarify
whether or not genotoxicity occurs in vivo and if there is a threshold for the effects observed in the
target organs in the long-term bioassays. Therefore, an in vivo Comet assay in F344/N rats covering
these target organs is required in addition to an in vivo bone marrow assay with oral application.
Owing to structural similarities and lack of data, the remaining substances cannot presently be
evaluated through the Procedure [FL-no: 02.083, 02.101, 02.214, 07.033, 07.035, 07.094, 07.098,
07.112, 07.129, 07.140, 07.172, 07.175, 07.196, 07.202, 07.255 and 09.821]. Additional data on
genotoxicity are requested for representative substances of this subgroup according to the opinion of
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the Panel on the Genotoxicity Test Strategy for Substances Belonging to Subgroups of FGE.19
(EFSA, 2008b).
4. Additional data considered by the Panel in FGE.212Rev110
4.1. Presentation of the additional data
Honma et al. (1999a, b) found that isophorone did not clearly induce mutations in the mouse
lymphoma assay (MLA) following 3 hour treatments, but observed that it was mutagenic after 24 hour
treatments in the absence of S9. Although only graphs are plotted, it seems that increases in mutation
frequency (MF) that exceeded the Global Evaluation Factor (GEF) occurred at around 1250–
1500 μg/ml at which point toxicity (as measured by relative survival) reached 70–90 %. 
The NTP conducted a mouse bone marrow chromosomal aberration (CA) study on isophorone.
Groups of 8 male B6C3F1 mice (larger group sizes than required by OECD) were dosed via
intraperitoneal (i.p.) injection with isophorone at 125, 250 and 500 mg/kg bw. The standard protocol
for in vivo CA is not given on the NTP website. However, based on Shelby and Witt (1995), animals
should have been sampled at 17 hours and, if negative, also at 36 hours. The data on the NTP website
are for bone marrow sampled at 36 hours only. It is therefore possible that a 17-hour sample was also
taken, and found to be negative, and that the data were not posted. Fifty cells per animal were scored
for CA and no increases in CA were seen. No measures of toxicity were recorded, but i.p. dosing
should have guaranteed systemic exposure. The control CA frequency was normal (2.75 %) and the
positive control (dimethylbenzanthracene) produced a significant response in CA frequency.
A DNA binding study was conducted in which F344 rats and B6C3F1 mice (the strains used in the
NTP carcinogenicity study) were exposed to isophorone (Thier et al., 1990). Animals of both sexes
were dosed once or five times by gavage with 500 mg/kg bw of unlabelled isophorone spiked with
[1,3,5‐14C]‐isophorone (specific activity 52 mCi per mmol, 1.92 GBq per mmol). An additional group
of acute dosed male rats received undiluted 14C‐isophorone for increased sensitivity. Rats and mice
were maintained for 24 hours in closed metabolic cages. Twenty-four hours after exposure, livers and
kidneys (the tumour target tissues) were removed from the animals. DNA was isolated through
hydroxyapatite chromatography and radioactivity was measured by liquid scintillation counting. No
positive controls were included. In addition, no untreated controls were included, but, except for the
liver sample of one mouse in the five times dose group, radioactivity values were within 2σ of 
background (6 dpm). Radioactivity values therefore did not indicate significant attachment of
radioactivity to DNA. From these results it can be concluded that neither isophorone nor its
metabolites bind covalently to DNA.
In addition, a report by Morishita et al. (1997) submitted to EPA (1997) is relevant and appears to
have been previously submitted only as an abstract. This study was designed to investigate whether
isophorone and/or α2μ‐globulin11 might be involved in the induction of preputial gland tumours in
F344 rats (10/sex/dose group). A series of experiments was performed in order to study several
parameters including:
• Binding of isophorone to DNA in the kidney and preputial gland. Groups of 10 male rats were
dosed by gavage with 500 mg/kg of [14C]‐isophorone (specific activity 14.65 mCi/mmol;
100 μCi/animal). Positive control animals were dosed with 3H‐labelled methyl nitrosourea.
• DNA adduct detection by 32P‐postlabelling in young adult male and female rats (7 per group)
dosed by gavage with 0, 250 or 500 mg/kg isophorone for five days.
10 The data presented in Section 4 are cited from revision 1 of FGE.212 (FGE.212Rev1). These data are the basis for the
conclusions in FGE.212Rev1 requesting additional genotoxicity data.
11 Since interaction with α2µ-globulin is not of direct relevance for the evaluation of genotoxic potential, this information is
omitted from this study summary.
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Extraction of preputial gland and kidney DNA from rats treated with single 500 mg/kg labelled doses
yielded no evidence of isophorone binding to DNA, whereas the positive control showed significant
binding to DNA of preputial gland and kidney. These negative results with isophorone were confirmed
in the 32P‐postlabelling assays.
In addition Industry has also asked whether the information submitted for isophorone (cyclohexenyl
derivative) could also be applied to evaluate the genotoxic potential of the five-carbon-membered ring
substances (i.e. cyclopentenyl derivatives) in subgroup 2.6 (letter from the European Flavour and
Fragrance Association (EFFA) to EFSA, dated 14 April 2010). This request was supported by the
argumentation that there is structural resemblance with respect to steric hindrance around the α,β-
unsaturated double bond. In addition, Industry argued that the π-conjugation systems in these
molecules are very nearly planar and, therefore, that the reactivity and genotoxic potentials of the five-
and six-membered ring systems would be similar. No further data were provided to substantiate this
argumentation.
4.2. Discussion of the additional data
Conflicting results were reported in two valid studies with the mouse lymphoma assay (MLA): one
negative (O’Donoghue et al., 1988) and one positive (NTP, 1986), at comparable concentrations.
Mixed results were also reported in two studies of limited validity: one negative (Honma et al., 1999a)
and one positive (Honma et al., 1999b). Another negative result was reported in a study (McKee et al.,
1987) the validity of which cannot be evaluated. In the light of the clearly negative results in two valid
bacterial gene mutation tests (Ames test) and in a valid sex-linked recessive lethal mutations test
(SLRL) in Drosophila, and taking into account the lack of specificity and high sensitivity of the MLA,
overall the results currently available are considered of questionable relevance. The Panel agrees that
isophorone demonstrates some genotoxic activity in vitro but that the new data demonstrate lack of
clastogenicity in vivo. In addition, the new DNA-binding data from two separate studies provide
convincing evidence that isophorone does not induce tumours via a genotoxic mechanism. On the
basis of these data it may be argued that there is no need to perform further in vivo genotoxicity
studies, such as the Comet assay or bone marrow micronucleus test. Thus, based on the data available,
the Panel concluded that there is no concern with respect to genotoxicity of isophorone.
4.3. Conclusion on additional data
Since, based on the additional information, the concern for the genotoxic potential for isophorone has
been alleviated, a genotoxic potential can also be ruled out for the other six-carbon members of
subgroup 2.6 related to isophorone [FL-no: 02.083, 02.101, 07.035, 07.098, 07.126, 07.129, 07.172,
07.175, 07.196, 07.202 and 07.255].
The Panel also concluded that isophorone can be considered only representative of the six-carbon ring
members of subgroup 2.6. The argumentation of Industry that this conclusion should be extended to
the cyclopentenyl derivatives in this subgroup [FL-no: 07.033, 07.094, 07.112 and 07.140] was
considered too limited, given the lack of supporting experimental data. Therefore, additional
genotoxicity tests are still required for the representative substance [FL-no: 07.112] already chosen by
the Panel. Alternatively, a more thorough explanation (physico-chemical parameters; experimental
underpinning) of the proposed similar reactivity of six- and five-membered ring substances should be
provided by Industry. In addition, for the substance [FL-no: 02.214] additional data on genotoxicity
are still required.
5. Additional data considered by the Panel in FGE.212Rev2
In response to the EFSA request in FGE.212 and FGE.212Rev1 for additional genotoxicity data for
subgroup 2.6, the Flavour Industry (IOFI, 2012) has submitted in vitro genotoxicity data on vetiveryl
acetate [FL-no: 09.821], which is structurally related to vetiverol [FL-no: 02.214]. These data were
evaluated in FGE.212Rev2, but, after the publication of the opinion, the Flavour Industry informed
EFSA that information previously submitted to the European Commission, and on which EFSA’s
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previous evaluation was based, was incorrect regarding the name, structure and composition of these
substances. The use of these two substances as chemically defined flavouring substances is no longer
supported by Industry (EFFA, 2014). Accordingly, these two substances will not be considered further
in this FGE.
6. Additional data considered by the Panel in FGE.212Rev3
6.1. Bacterial reverse mutation assay
In order to investigate the potential of 3-methyl-2-cyclopenten-1-one [FL-no: 17.112] to induce gene
mutations in bacteria, an Ames test was performed in accordance with OECD Test Guideline 471
(OECD, 1997) and following Good Laboratory Practice (GLP) in five strains of Salmonella
Typhimurium (TA98, TA100, TA1535, TA1537 and TA102) in the presence or absence of metabolic
activation by S9-mix in two separate experiments. In experiment 1, the “plate incorporation assay”
was applied. In experiment 2, treatment with S9-mix included a pre-incubation step (20 minutes at
37 °C). Seven different concentrations of the test substance were tested using appropriate positive
control chemicals and purified water as a negative control. The highest concentration selected was
5000 µg/plate (range 5 to 5000 µg/plate and 80 to 5000 µg/plate in experiments 1 and 2, respectively).
All positive control chemicals induced significant increases in revertant colony numbers, confirming
the sensitivity of the tests and the efficacy of the S9-mix, while the negative controls were within the
normal ranges. After treatment with 3-methyl-2-cyclopenten-1-one in experiment 1, evidence of
toxicity, in the form of diminished background bacterial lawn, was observed at 5000 µg/plate in both
the presence and absence of S9-mix in all strains; in addition, strain TA98 also showed toxicity at 160,
500 and 1600 µg/plate. At most experimental points, at the same concentrations the number of
revertant colonies was relatively low. In experiment 2, toxicity was observed at 5000 µg/plate in all
strains but TA102, in both the presence and absence of S9-mix (Bowen, 2014).
No increase in revertant colony numbers was observed at any concentration tested in either the
presence and absence of S9-mix. Therefore, it was concluded that 3-methyl-2-cyclopenten-1-one has
no mutagenic activity under the conditions employed.
6.2. In vitro micronucleus assay in human lymphocytes
The in vitro micronucleus assay was carried out in accordance with OECD Test Guideline 487
(OECD, 2010) and following GLP. Duplicate cultures of human peripheral blood lymphocytes,
prepared from the pooled blood of two female donors and stimulated with phytohaemagglutinin
(PHA), were treated with purified water (negative control), 3-methyl-2-cyclopenten-1-one or
appropriate positive controls (mitomycin C and noscapine as clastogenic and aneugenic chemicals,
respectively, in the absence of S9-mix; cyclophosphamide as a clastogenic chemical in the presence of
S9-mix). A single experiment was performed 48 hours after mitogen stimulation, following two
treatment schedules: 3 + 21 hours in the presence and absence of S9-mix and 24 + 0 hours without S9-
mix. Micronuclei were analysed at three concentrations (600, 800 and 962 µg/ml; the highest
concentration is equivalent to 10 mM) chosen on the basis of a preliminary cytotoxicity range-finder
experiment. Applying the 3 + 21 hours treatment, the cultures were exposed to 3-methyl-2-
cyclopenten-1-one for 3 hours in either the presence or the absence of the S9-mix. In the 24 + 0 hours
treatment cultures were continuously exposed to 3-methyl-2-cyclopenten-1-one for 24 hours without
the S9-mix. In all cases, the cells were harvested 24 hours after the beginning of treatment (i.e. 72
hours after culture initiation). Four thousand binucleated cells per concentration were analysed. All
positive control chemicals induced statistically significant increases in the frequency of
micronucleated cells, confirming the sensitivity of the tests and the efficacy of the S9-mix, while the
negative controls were within 95th percentile of the current observed historical vehicle control ranges.
At any concentration tested in both the presence and absence of S9-mix, the frequency of binucleated
cells with micronuclei was comparable to that of negative controls (values of p ≤ 0.05 were considered 
significant). It was concluded that 3-methyl-2-cyclopenten-1-one did not induce micronuclei in
cultured human peripheral blood lymphocytes when tested at concentrations up to 10 mM under the
experimental conditions employed (Watters, 2014).
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The results of the two studies described above are summarised in Table 8.
CONCLUSION
The genotoxicity of the flavouring substance 3-methyl-2-cyclopenten-1-one [FL-no: 07.112] was
assessed by means of two in vitro assays (gene mutations in bacteria and micronuclei in human
lymphocytes). 3-Methyl-2-cyclopenten-1-one did not induce gene mutations in bacteria with or
without metabolic activation when tested under the conditions employed in the study as presented by
the applicant. Nor did it induce micronuclei in cultured human blood lymphocytes under the test
conditions employed with or without metabolic activation for this study. Therefore, there is no concern
with respect to genotoxicity and the substance 3-methyl-2-cyclopenten-1-one [FL-no: 07.112] can be
evaluated through the Procedure. This conclusion is also valid for the other four five-carbon ring
substances isojasmone [FL-no: 07.033], 3-methyl-2-(pent-2(cis)-enyl)cyclopent-2-en-1-one [FL-no:
07.094], 3-methyl-2-pentylcyclopent-2-en-1-one [FL-no: 07.140] and trans-3-methyl-2-(2-pentenyl)-
2-cyclopenten-1-one [FL-no: 07.219]. Based on the available data all 22 substances of this FGE are no
longer of concern with respect to genotoxic and, therefore, they can be evaluated through the
Procedure.
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SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (JECFA, 1999, 2003, 2009)
Table 3: Summary of safety evaluation applying the Procedure
FL-no
JECFA-no
EU Register name Structural formula MSDI (a)
(µg/capita/day)
Class (b),
Evaluation procedure path (c)
Outcome on the named
compound (d) or (e)
02.062
381
Carveol 9.5
140
Class I
A3: intake below threshold
d
02.083
434
p-Menth-1-en-3-ol 0.012
0.02
Class I
A3: intake below threshold
d
02.101
1404
Pin-2-en-4-ol 0.012
0.2
Class I
A3: intake below threshold
d
09.143
383
Carvyl propionate 0
0.04
Class I
A3: intake below threshold
d
09.215
382
Carvyl acetate 4
36
Class I
A3: intake below threshold
d
09.870 Carvyl-3-methylbutyrate 0.0012 Class I
A3: intake below threshold
d
OH
OH
HO
O
O
OO
O
O
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FL-no
JECFA-no
EU Register name Structural formula MSDI (a)
(µg/capita/day)
Class (b),
Evaluation procedure path (c)
Outcome on the named
compound (d) or (e)
07.033
1115
Isojasmone 0.37
0.01
Class II
A3: Intake below threshold
d
07.035
1111
Tetramethyl
ethylcyclohexenone
(mixture of isomers)
7.8
0.2
Class II
A3: Intake below threshold
d
07.094
1114
3-Methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-
one
13
7.2
Class II
A3: intake below threshold
d
07.098
1107
3-Methylcyclohex-2-en-
1-one
0.012
0.1
Class II
A3: intake below threshold
d
07.112
1105
3-Methyl-2-cyclopenten-
1-one
0.06
ND
Class II
A3: intake below threshold
d
07.126
1112
3,5,5-
Trimethylcyclohex-2-en-
1-one
4.6
0.1
Class II
A3: intake below threshold
d
07.129
1113
3-Methyl-5-
propylcyclohex-2-en-1-
one
0.097
4.1
Class II
A3: intake below threshold
d
O
+
O
OO
29 % 68 %
+
O
O
O
O
O
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FL-no
JECFA-no
EU Register name Structural formula MSDI (a)
(µg/capita/day)
Class (b),
Evaluation procedure path (c)
Outcome on the named
compound (d) or (e)
07.140
1406
3-Methyl-2-
pentylcyclopent-2-en-1-
one
0.34
0.2
Class II
A3: intake below threshold
d
07.172
1110
4-Isopropylcyclohex-2-
en-1-one
0.0012
0.001
Class II
A3: intake below threshold
d
07.175
435
p-Menth-1-en-3-one 44
10
Class II
A3: intake below threshold
d
07.196
1870
Pin-2-en-4-one 15 Class II
A3: intake below threshold
d
07.202 2,6,6-
Trimethylcyclohex-2-en-
1-one
0.12 Class II
A3: intake below threshold
d
07.255
1856
l-Piperitone 12 Class II
A3: intake below threshold
d
07.146
380.1
d-Carvone 2390
9900
Class II
A3: intake above threshold, A4:
not endogenous, A5: adequate
NOAEL exists
d
O
O
O
O
O
O
R
O
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FL-no
JECFA-no
EU Register name Structural formula MSDI (a)
(µg/capita/day)
Class (b),
Evaluation procedure path (c)
Outcome on the named
compound (d) or (e)
07.147
380.2
l-Carvone 2390
9900
Class II
A3: Intake above threshold, A4:
Not endogenous, A5: Adequate
NOAEL exists
d
07.219 trans-3-Methyl-2-(2-
pentenyl)-2-cyclopenten-
1-one
4.7
No evaluation
(a): EU MSDI: amount added to food as flavour in (kg/year) × 10E9/(0.1 × population in Europe (= 375 × 10E6) × 0.6 × 365) = µg/capita/day.
(b): Thresholds of concern: Class I = 1 800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
O
O
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QSAR PREDICTIONS ON MUTAGENICITY IN FIVE MODELS FOR 16 KETONES FROM SUBGROUP 2.6
Table 4: QSAR predictions on mutagenicity in five models for subgroup 2.6
FL-no
JECFA-no
EU Register name Structural formula (a) ISS Local
Model Ames
Test TA100 (b)
MultiCASE
Ames test (c)
MultiCASE
Mouse
lymphoma
test (d)
MultiCASE
Chromosomal
aberration test
in CHO (e)
MultiCASE
Chromosomal
aberration test
in CHL (f)
Not in
Register
2,6-Dimethyl-9-(1-
methylethylidene)-
bicyclo[5.3.0]dec-2-en-4-one
OD NEG NEG NEG NEG
07.033
1115
Isojasmone OD NEG NEG NEG NEG
07.094
1114
3-Methyl-2-(pent-2(cis)-
enyl)cyclopent-2-en-1-one
OD NEG OD NEG NEG
07.098
1107
3-Methylcyclohex-2-en-1-one OD NEG POS NEG EQU
07.112
1105
3-Methyl-2-cyclopenten-1-one OD NEG POS NEG EQU
07.126
1112
3,5,5-Trimethylcyclohex-2-en-
1-one
OD NEG POS NEG EQU
07.129
1113
3-Methyl-5-propylcyclohex-2-
en-1-one
OD NEG POS NEG EQU
O
O
O
O
O
O
O
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FL-no
JECFA-no
EU Register name Structural formula (a) ISS Local
Model Ames
Test TA100 (b)
MultiCASE
Ames test (c)
MultiCASE
Mouse
lymphoma
test (d)
MultiCASE
Chromosomal
aberration test
in CHO (e)
MultiCASE
Chromosomal
aberration test
in CHL (f)
07.140
1406
3-Methyl-2-pentylcyclopent-2-
en-1-one
OD NEG OD NEG NEG
07.146
380.1
d-Carvone OD NEG NEG NEG NEG
07.147
380.2
l-Carvone OD NEG NEG NEG NEG
07.172
1110
4-Isopropylcyclohex-2-en-1-one OD NEG NEG NEG EQU
07.202 2,6,6-Trimethylcyclohex-2-en-
1-one
OD NEG OD NEG NEG
07.035
1111
Tetramethyl
ethylcyclohexenone (mixture of
isomers)
OD NEG NEG NEG NEG
07.255 l-Piperitone OD NEG OD NEG EQU
O
O
O
O
O
OO
29 % 68 %
+
O
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FL-no
JECFA-no
EU Register name Structural formula (a) ISS Local
Model Ames
Test TA100 (b)
MultiCASE
Ames test (c)
MultiCASE
Mouse
lymphoma
test (d)
MultiCASE
Chromosomal
aberration test
in CHO (e)
MultiCASE
Chromosomal
aberration test
in CHL (f)
07.196 Pin-2-en-4-one OD NEG POS NEG POS
07.175 p-Menth-1-en-3-one OD NEG POS NEG OD
(a): Structural group 2.6: α,β-unsaturated alicyclic ketones.
(b): Local model on aldehydes and ketones, Ames test TA100 (NEG, negative; POS, positive; OD, out of domain).
(c): MultiCASE Ames test (OD, out of domain; POS, positive; NEG, negative; EQU, equivocal).
(d): MultiCASE mouse lymphoma test (OD, out of domain; POS, positive; NEG, negative; EQU, equivocal).
(e): MultiCASE chromosomal aberration in CHO (OD, out of domain; POS, positive; NEG, negative; EQU, equivocal).
(f): MultiCASE chromosomal aberration in CHL (OD, out of domain; POS, positive; NEG, negative; EQU, equivocal).
OD: out of applicability domain: not matching the range of conditions where a reliable prediction can be obtained in this model. These conditions may be physico-chemical, structural, biological,
etc.
O
O
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CARCINOGENICITY STUDIES CONSIDERED BY THE PANEL IN FGE.212
Table 5: Carcinogenicity studies
Chemical name [FL-no] Species, sex,
no/group
Route Dose levels Duration Results Reference Comments (a)
3,5,5-Trimethylcyclohex-
2-en-1-one [07.126]
Rats,
male + female,
50/sex/group
Gavage
in maize
oil
0 (controls), 250 or
500 mg/kg bw/day,
five times per week
103 weeks Males: increased incidences of renal tubular
cell adenomas and adenocarcinomas and of
carcinomas of the preputial gland
Females: no carcinogenic effect
NTP
(1986)
Valid
Mice,
male + female,
50/sex/group
Gavage
in maize
oil
0 (controls), 250 or
500 mg/kg bw/day,
five times per week
103 weeks Males: Increased incidences of
hepatocellular adenomas and carcinomas,
mesenchymal tumours in the integumentary
system and malignant lymphomas
Females: no carcinogenic effect
NTP
(1986)
Valid
d-Carvone [07.146] Mice,
male + female,
50/sex/group
Gavage 0, 375 or
750 mg/kg bw/day,
five times per week
103 weeks Males and females: no increases in tumour
incidences
NTP
(1990)
Valid
(a): Validity of genotoxicity studies:
• Valid.
• Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or there is limited documentation).
• Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or the test system is inappropriate).
• Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too few experimental details provided).
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GENOTOXICITY DATA (IN VITRO) CONSIDERED BY THE PANEL IN FGE.212
Table 6: Summary of genotoxicity data (in vitro)
Chemical name
[FL-no]
Test system Test object Concentration Reported
result
Reference Comments (e)
Tetramethyl
ethylcyclohexenone
(mixture of isomers)
[07.035]
Reverse mutation S. typhimurium TA98,
TA100, TA1535, TA1537,
TA1538
Five concentrations
up to cytotoxicity or
maximum
3 600 µg/plate
Negative (a) Wild et al. (1983) Limited validity (no TA102
or Escherichia coli);
possibly slightly low
maximal concentration
tested
3,5,5-
Trimethylcyclohex-2-en-
1-one [07.126]
Reverse mutation S. typhimurium TA97,
TA98, TA100, TA1535,
TA1537
33–10 000 µg/plate Negative (a) Mortelmans et al.
(1986)
Valid
Mutation S. typhimurium TA98,
TA100, TA1535, TA1537
33–10 000 µg/plate Negative (a) NTP (1986) NTP study carried out in
accordance with standard
US EPA Guideline; result is
considered valid
Mutation L5178YTk+/– mouse
lymphoma cells
67–810 µg/ml Negative (b) McKee et al.
(1987)
Validity cannot be evaluated
(tested with S9; abstract only
with very limited
information)
Mutation L5178YTk+/– mouse
lymphoma cells
130–1 300 µg/ml Negative (c) McKee et al.
(1987)
Validity cannot be evaluated
(tested without S9; abstract
only with very limited
information)
Mutation L5178YTk+/– mouse
lymphoma cells
0.089–0.89 µl/ml Negative (c) O’Donoghue et al.
(1988)
Valid according to current
guidelines
Mutation L5178YTk+/– mouse
lymphoma cells
0.13–1.3 µl/ml Negative (b) O’Donoghue et al.
(1988)
Valid according to current
guidelines
Mutation L5178YTk+/– mouse
lymphoma cells
1 200 µg/ml Positive (b) NTP (1986) NTP study carried out in
accordance with standard
US EPA Guideline; not
tested with S9. Result is
considered valid
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Chemical name
[FL-no]
Test system Test object Concentration Reported
result
Reference Comments (e)
Mutation L5178YTk+/– mouse
lymphoma cells
Not reported
(however, up to
cytotoxic
concentrations) for
three-hour exposure
Negative (a) Honma et al.
(1999a)
Limited validity since data
were presented in a
summarised table format
only (as a result of an
international collaborative
study)
Mutation L5178YTk+/– mouse
lymphoma cells
Up to 1 500 µg/ml Positive (b) Honma et al.
(1999b)
Limited validity.
Isophorone was mutagenic
after 24-hour treatments in
the absence of S9. Although
only graphs are plotted, it
seems that increases in MF
that exceeded the GEF
occurred at around 1 250–
1 500 μg/ml, at which point 
toxicity (measured by
relative survival) reached
70–90 %
Chromosomal
aberration
Chinese hamster ovary cells 5–1 600 µg/ml Negative (a) Gulati et al.
(1989)
Limited validity (not clear if
gaps were included in the
scores)
Chromosomal
aberration
Chinese hamster ovary cells 250–1 600 µg/ml Negative (a) NTP (1986) NTP study carried out in
accordance with standard
US EPA Guideline; result is
considered valid
Chromosomal
aberration
Chinese hamster lung
fibroblasts
0–1 250 (b) µg/ml
0–1 500 (c) µg/ml
Positive (a) Matsuoka et al.
(1996)
Valid
Chromosomal
aberration
Chinese hamster lung
fibroblasts
250–1 000 mg/ml Negative (a) Matsuoka et al.
(1996)
Valid. Exposed to
isophorone without
metabolic activation for 24
or 48 hours; cytotoxic at
highest concentrations
Sister chromatid
exchange
Chinese hamster ovary cells 5–1 600 mg/ml Positive (b) (d) Gulati et al.
(1989)
Valid (positive, –S9;
negative, +S9)
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Chemical name
[FL-no]
Test system Test object Concentration Reported
result
Reference Comments (e)
Sister chromatid
exchange
Chinese hamster ovary cells 160–1 000 mg/ml Negative (a) NTP (1986) NTP study carried out
according to standard US
EPA Guideline; result is
considered valid
Unscheduled DNA
synthesis
Rat hepatocytes 0.005–0.4 µl/ml Negative O’Donoghue et al.
(1988)
Valid according to current
guidelines
Unscheduled DNA
synthesis
Rat hepatocytes 5–200 µl/ml Negative (a) McKee et al.
(1987)
Validity cannot be evaluated
(abstract only with very
limited information)
Carvone (isomer not
specified)
Gene mutation S. typhimurium TA1535,
TA1537, TA98, TA100
3 µmol/plate Negative Florin et al.
(1980)
Insufficient validity (spot
test, not in accordance
OECD Guideline, methods
and results insufficiently
reported). Isomer (D or L)
not reported
Rec assay Bacillus subtilis H17 (rec+)
and M45 (rec–)
0.6 ml/disc Negative Matsui et al.
(1989)
The test system used is
considered inappropriate
d-Carvone [07.0146] Gene mutation S. typhimurium TA1535,
TA98, TA100, TA1537
333 µg/plate Negative (a) NTP (1990) Valid
Gene mutation (pre-
incubation)
S. typhimurium TA1535,
TA98, TA100, TA1537
560 µg/plate Negative Mortelmans et al.
(1986)
Valid
Sister chromatid
exchange
Chinese hamster ovary cells 502 µg/ml Positive (a) NTP (1990) Valid
Chromosomal
aberration
Chinese hamster ovary cells 400 µg/ml Positive (a) NTP (1990) Valid
(a): With and without metabolic activation.
(b): Without metabolic activation.
(c): With metabolic activation.
(d): Cytotoxic at next highest dose tested (1600 mg/ml).
(e): Validity of genotoxicity studies:
• Valid.
• Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or there is limited documentation).
• Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or the test system is inappropriate).
• Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too few experimental details provided).
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GENOTOXICITY DATA (IN VIVO) CONSIDERED BY THE PANEL IN FGE.212 AND IN FGE.212REV1
Table 7: Summary of genotoxicity data (in vivo)
Chemical name [FL-no] Test system Test object Route Dose Result Reference Comments (a)
Tetramethyl
ethylcyclohexenone
(mixture of isomers)
[07.035]
Sex-linked
recessive lethal
mutation
Drosophila
melanogaster
Feed 10 mM Negative Wild et al.
(1983)
Limited validity (low number of
chromosomes, limited reporting)
Micronucleus
formation
Mouse bone
marrow
i.p. 180, 307 and
450 mg/kg bw
Negative Wild et al.
(1983)
Limited validity. Only analysis at one
time point; no PCE/NCE ratio
reported
3,5,5-Trimethylcyclohex-
2-en-1-one [07.126]
Sex-linked
recessive lethal
mutation
Drosophila
melanogaster
2000 and 1250 ppm Negative Foureman et
al. (1994)
Valid; however, only limited
relevance
Micronucleus
formation
CD-1 mice i.p. 540 mg/kg bw
(MTD)
Negative McKee et al.
(1987)
Validity cannot be evaluated.
Abstract only; very limited
information, no data on PCE/NCE
ratio
CD-1 mice i.p. 0.54 ml/kg bw Negative O’Donoghue
et al. (1988)
Limited validity. Only one dose level
tested, this dose level corresponded to
the LD20; sample schedule
inadequate
Chromosomal
aberration
B6C3F1 mice i.p. 125, 250 and
500 mg/kg bw
Negative NTP website Valid. Submitted by the Flavour
Industry in 2009. The standard
protocol for in vivo CA is not given
on the NTP website. However, based
on Shelby and Witt (1995), animals
should have been sampled at 17 hours
and, if negative, also at 36 hours. The
data on the NTP website are only for
bone marrow sampled at 36 hours. It
is therefore possible that a 17-hour
sample was also taken, and found to
be negative, but that these data were
not posted. Fifty cells per animal
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Chemical name [FL-no] Test system Test object Route Dose Result Reference Comments (a)
were scored for CA and no increases
in CA were seen. No measures of
toxicity were recorded, but i.p. dosing
should have guaranteed systemic
exposure
DNA binding F344 rats Gavage 500 mg unlabelled
isophorone/kg bw
spiked with 14C-
isophorone
(0.4 mCi/rat)
Negative Thier et al.
(1990)
Limited validity. Submitted by
Industry in 2009. No positive controls
and no untreated controls used. Liver
and kidney were analysed
DNA binding B6C3F1 mice Gavage 500 mg unlabelled
isophorone/kg bw
spiked with 14C-
isophorone
(0.08 mCi/mouse)
Negative Thier et al.
(1990)
Limited validity. Submitted by
Industry in 2009. No positive controls
and no untreated controls used. Liver
and kidney were analysed
DNA binding F344 rats (10
males)
Gavage 500 mg/kg bw 14C-
isophorone
(0.1 mCi/rat)
Negative Morishita et
al. (1997);
cited by EPA
(1997)
Valid. Preputial glands and kidneys
were analysed
DNA adducts
(32P-
postlabelling)
F344 rats (7
males and 7
females per
dose group)
Gavage 0 and 500 mg/kg/day
for 5 days.
Negative Morishita et
al. (1997);
cited by EPA
(1997)
Valid. Preputial glands were analysed
(a): Validity of genotoxicity studies:
• Valid.
• Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or there is limited documentation).
• Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or the test system is inappropriate).
• Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too few experimental details provided).
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GENOTOXICITY DATA (IN VITRO) CONSIDERED BY THE PANEL IN FGE.212REV3
Table 8: Summary of genotoxicity data (in vitro)
Chemical name [FL-no] Test system Test object Concentration Reported
result
Reference Comments
3-Methyl-2-cyclopenten-
2-one [07.112]
Reverse mutation S. typhimurium TA98,
TA100, TA1535, TA1537,
TA102
5–5 000 µg/plate Negative (a) Bowen (2014) TA98 showed toxicity at
160 µg/ml
Micronucleus assay Human peripheral blood
lymphocytes
600, 800 and
962 µg/plate
Negative Watters (2014)
(a): With and without metabolic activation.
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ABBREVIATIONS
bw body weight
CA chromosomal aberration
CAS Chemical Abstracts Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHL Chinese hamster lung cells
CHO Chinese hamster ovary (cells)
CoE Council of Europe
DNA deoxyribonucleic acid
DTU Danish Technical University
EC European Commission
EFFA European Flavour and Fragrance Association
EU European Union
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GEF global evaluation factor
ID identity
IOFI International Organization of the Flavour Industry
i.p. intraperitoneal
IR infrared spectroscopy
ISS Istituto Superiore di Sanità
JECFA The Joint FAO/WHO Expert Committee on Food Additives
MLA mouse lymphoma assay
MLTK mouse lymphoma thymidine kinase
MS mass spectrometry
MTD maximum tolerated dose
NCE normochromatic erythrocytes
NFI National Food Institute
NMR nuclear magnetic resonance
No number
NOAEL No Observed Adverse Effect Level
NTP National Toxicology Program
OECD Organisation for Economic Co-operation and Development
PCE polychromatic erythrocytes
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(Q)SAR quantitative structure–activity relationship
SCE sister chromatid exchange
WHO World Health Organization
